Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study
Wenmin Chen(Guangzhou University of Chinese Medicine), Lizhu Lin(First Affiliated Hospital of Guangzhou University of Chinese Medicine), Jietao Lin(First Affiliated Hospital of Guangzhou University of Chinese Medicine), Xiangjun Qi(Guangzhou University of Chinese Medicine), Lingling Sun(Second Affiliated Hospital of Zhejiang University), Ze xin Zhang(Guangzhou University of Chinese Medicine), Hanrui Chen(First Affiliated Hospital of Guangzhou University of Chinese Medicine), Yang Cao(First Affiliated Hospital of Guangzhou University of Chinese Medicine), Zhiwei Xiao(First Affiliated Hospital of Guangzhou University of Chinese Medicine), Lanting Tao(Guangzhou University of Chinese Medicine), Ting Yang(Guangzhou University of Chinese Medicine)
Cited by 6
Related Papers
Machine learning and SHAP value interpretation for predicting comorbidity of cardiovascular disease and cancer with dietary antioxidants
|Redox Biology|2024|193
Network pharmacology based research into the effect and mechanism of Yinchenhao Decoction against Cholangiocarcinoma
|Chinese Medicine|2021|95
The associations between dietary fibers intake and systemic immune and inflammatory biomarkers, a multi-cycle study of NHANES 2015–2020
|Frontiers in Nutrition|2023|41
Prognostic factors for survival among patients with primary bone sarcomas of small bones
|Cancer Management and Research|2018|31